Patient description: 19 yo Hispanic female G1P1 at 32+ 6 weeks of gestational age presented to the OB clinic for routine follow up complaining of mild headache and leg swelling. Primary evaluation revealed BP of 146/99 and urine dipstick with 3+ proteins. Her BP and U/A were normal in previous visit. Repeat BP a few hours later is 150/100 mmHg. Laboratory studies showed a normal hematocrit, platelet count, and liver transaminase levels. She is complaining of fatigue but no fever or chills. She is also suffering of headaches with no vision changes. No shortness of breath, cough, chest pain, orthopnea and palpitations or skin rash were observed. Her physical exam was negative for abdominal pain, change in bowel habits, nausea, vomiting, dysuria, frequency, hematuria or frothy urine. Leg swelling was observed with no arthralgia or back pain. She has no specific past medical issues and only uses prenatal vitamins. Her family history is positive for DM type 2 and HTN. She is a social alcohol consumer with the negative history of smoking or drug use. She is only have one partner in past 2 years and didn't have any contraceptive methods since 2 years ago. Her BMI was 24 at the first

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Type 1 Diabetes Pregnancy Age ≥ 18 and ≤ 45 years at the time of screening Clinical diagnosis of type 1 diabetes Currently using an insulin pump at the time of screening HbA1c ≤ 9%, as performed by point of care or central laboratory testing Pregnant 14+0/7 to 32+6/7 weeks gestation Singleton pregnancy without any other significant known complications, such as preeclampsia, premature rupture of membranes, 2nd/3rd trimester bleeding, fetal growth or fluid abnormalities No proven or suspected fetal malformations diagnosed in the current pregnancy Bolus for all meals and snacks that contain ≥ 5 grams of carbohydrate Willing to switch to, or continue Novolog or Humalog for the closed-loop session Willingness not to start any new non-insulin glucose-lowering agent during the course of the trial  Known unstable cardiac disease or untreated cardiac disease, as revealed by history or physical examination Concurrent use of Afrezza or any non-insulin glucose-lowering agent other than metformin (including GLP-1 agonists, Pramlintide, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas) Hemophilia or any other bleeding disorder Prior history of Preterm Premature Rupture of Membranes (PPROM) Significant hyperemesis interfering with carbohydrate intake Laboratory results: 1. A1C > 9% 2. Abnormal liver or renal function (Transaminase >2 times the upper limit of normal, creatinine > 1.5 mg/dL) 3. Liver and renal function testing drawn at screening visit or within three months prior to screening (for other purposes) will suffice for enrollment purposes Dermatological conditions that would preclude wearing a CGM sensor or infusion site Any condition that could interfere with participating in the trial, based on investigator judgment Participation in another pharmaceutical or device trial at the time of enrollment or during the study Having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first-degree relative who is directly involved in conducting the clinical trial